A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Clinical trial NCT07160257 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07160257
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-05
- Primary completion
- 2026-11-15
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.